Pirlimycin
Pirlimycin is a lincosamide antibiotic specifically formulated for intramammary infusion in lactating dairy cattle. It is primarily utilized for the treatment of clinical and subclinical mastitis caused by susceptible gram-positive organisms. * **Key Pathogens**: Highly active against *Staphylococcus* species (including *S. aureus*, *S. epidermidis*, *S. chromogenes*, *S. hyicus*, *S. xylosus*), *Streptococcus* species (*S. agalactiae*, *S. dysgalactiae*, *S. uberis*, *S. bovis*), and *Enterococcus faecalis*. * **Clinical Pearl**: Unlike some older mastitis formulations, pirlimycin exhibits excellent tissue penetration, allowing it to reach deep-seated infections within the udder parenchyma rather than just remaining in the milk compartment. > **Note**: Organisms with a MIC of ≤ 2 mcg/mL are considered susceptible, while those with a MIC ≥ 4 mcg/mL are considered resistant.
Mecanismo: Pirlimycin shares its mechanism of action with other **lincosamide** antibiotics (such as clindamycin and lincomycin). * **Mechanism**: Binds reversibly to the **50S ribosomal subunit** of susceptible bacterial RNA. * **Pathway**: Inhibits peptidyl transferase → prevents peptide bond formation → **interferes with bacterial protein synthesis**. * **Activity**: Generally considered **bacteriostatic**, but can be bactericidal at high concentrations against highly susceptible organisms. It is a time-dependent antibiotic.
Dosificación por especie
- Clinical and subclinical mastitis · Infuse contents of one syringe into each affected quarter · Intramammary · q24h · Repeat after 24 hours. May be repeated daily for up to 8 consecutive days. · Use proper teat end preparation, sanitation, and intramammary infusion technique.
Las dosis son una referencia clínica para médicos veterinarios. Confirme siempre con la información vigente del producto y el paciente individual.
Vías de administración
Contraindicaciones
- Known hypersensitivity to lincosamides
Efectos adversos
- No adverse effects or udder irritation have been reported at labeled doses
Interacciones farmacológicas
- Erythromycin · Potential in vitro antagonism; may compete for the same ribosomal binding site
- Clindamycin · Potential in vitro antagonism; may compete for the same ribosomal binding site
Monitoreo
- Clinical efficacy (resolution of mastitis signs, somatic cell counts)
- Strict adherence to withdrawal periods
Sobredosis
No specific data is available regarding acute toxicity or overdosage. If an overdose occurs, monitor for signs of local irritation or systemic gastrointestinal upset, and observe extended withdrawal times.
La referencia de fármacos de VetSheet está destinada a médicos veterinarios como apoyo a la decisión clínica; no sustituye el juicio profesional ni la información vigente del fabricante.